TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16087057
Drug: ACTH treatment
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH treatment (n = 26)
Study: 16087057
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid treatment (n = 18)
Study: 12618533
Drug: High-dose ACTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ACTH
Study: 11821278
Drug: Continued administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued administration of vaginal progesterone for 3 weeks after positive HCG (control group, n = 153)
Study: 3929067
Drug: Chemo-immunotherapy consisting
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432
Study: 29709062
Drug: Chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy
Study: 26699690
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia combined with infusion of 1 μg/kg dexmedetomidine
Study: 18765877
Drug: 12 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/kg Ringer lactate iv (Group B)
Study: 18765877
Drug: 12 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/kg 4.5% hydroxyethylstarch (Hetastarch) iv (Group C)
Study: 18765877
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg Ringer lactate iv (Group A)
Study: 15885641
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid (prednisolone) therapy
Study: 12665325
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment strategy (DAD)
Study: 10378632
Drug: Ifosfamide (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 10 days (cohort A)
Study: 10378632
Drug: Ifosfamide (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 7 days (cohort B)
Study: 9081356
Drug: High uPA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High uPA tumours (uPA > 0.62 ng/mg protein)
Study: 9081356
Drug: Not treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not treated with systemic adjuvant therapy
Study: 30230026
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (n=56)
Study: 27342507
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of bortezomib
Study: 27342507
Drug: Reduction dose
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction dose of bortezomib
Study: 22248153
Drug: Avanafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (50 mg, 100 mg, 200 mg)
Study: 17891409
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1 g (Perfalgan)
Study: 8764800
Drug: 0.7% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% dorzolamide twice daily
Study: 3860335
Drug: Fluoride supplements
Normalized name: Fluoride supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride supplements (for children of mothers who received personal advice)
Study: 15945446
Drug: Short-term controlled
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term controlled treatment (DOTS)
Study: 15945446
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment regimens
Study: 15945446
Drug: Quadruple-combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple-combination therapy
Study: 15945446
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 5 antituberculous drugs
Study: 12527599
Drug: AeroDose 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroDose 90 mg
Study: 12527599
Drug: AeroDose 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroDose 30 mg
Study: 12527599
Drug: AeroDose 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroDose 60 mg
Study: 12527599
Drug: PARI LC
Normalized name: Pari LC Pediatric Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI LC PLUS 300 mg
Study: 12527599
Drug: AeroDose (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroDose (all doses)
Study: 10473238
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g single dose)
Study: 10473238
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg i.v. every 6 h for 48 h)
Study: 8888369
Drug: AMPT 1
Normalized name: AMPT
DrugBank: Racemetyrosine (DB16306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPT 1 g
Study: 8888369
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg (placebo)
Study: 1676083
Drug: Psychosocial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial stimulation (weekly play sessions at home with a community health aide)
Study: 6603287
Drug: Digoxin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (1 mg iv over 24 hr, then 0.25 mg/day) and Propranolol (10 mg every 6 hr)
Study: 26891420
Drug: Tivantinib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (360 mg/m² twice daily) plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Study: 26891420
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Study: 22182361
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Promotion (OHP) program implemented in nine schools since 2005
Study: 11016021
Drug: Aspirin 320
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 320 mg
Study: 18794027
Drug: Aspirin 0
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 0 mg
Study: 12818934
Drug: Intrathecal opioid
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal opioid (1 micro g/kg sufentanil with 8 micro g/kg preservative-free morphine)
Study: 8791955
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 1 g b.d.
Study: 8791955
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. plus amoxycillin 1 g b.d.
Study: 8791955
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg b.d. plus amoxycillin 1 g b.d.
Study: 1536485
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g i.v. magnesium sulfate infused over 20 minutes
Study: 6142700
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonist cimetidine in combination with H1 receptor antagonist chorpheniramine
Study: 20732932
Drug: AP-D (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP-D (pemetrexed 500 mg/m² plus doxorubicin 60 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Study: 20732932
Drug: AC-D (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-D (doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Study: 19916712
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac sodium at a dose of 2 x 75 mg and additional breakthrough meperidine at 50 mg dosages if necessary
Study: 19916712
Drug: Meperidine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 6 x 50 mg
Study: 11052428
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid warmers (Group 3, n = 37)
Study: 9261942
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (A/Yamagata/32/89, A/Beijing/352/89, B/Bangkok/163/90)
Study: 9261942
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (A/Beijing/352/89)
Study: 24385115
Drug: Clindamycin/tretinoin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/tretinoin gel patches
Study: 24385115
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel patches
Study: 24385115
Drug: Blank patches
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank patches (no gel)
Study: 22428144
Drug: Lutein diacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein diacetate (20 mg/day)
Study: 22428144
Drug: Crystalline lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline lutein (20 mg/day)
Study: 18430173
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (Restylane, 1.4 mL)
Study: 15888157
Drug: High-fluence laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fluence laser treatment
Study: 15888157
Drug: Low-fluence laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence laser treatment (Control)
Study: 12552211
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (ITB) 37.5 mg
Study: 10532441
Drug: Verteporfin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verteporfin (6 mg per square meter of body surface area) administered via intravenous infusion of 30 mL over 10 minutes.
Study: 10532441
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes.
Study: 10532441
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy for predominantly classic CNV lesions (area of classic CNV occupied 50% or more of the area of the entire lesion).
Study: 10532441
Drug: Verteporfin treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verteporfin treatment.
Study: 8828529
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (prednisone, median daily dose 20 mg, median duration 2 years)
Study: 1795470
Drug: basic therapies
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic therapies (nitrates + cardiac glycosides + diuretics)
Study: 25063274
Drug: Glucagon treatment
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon treatment in isolated rat pancreatic islets
Study: 25063274
Drug: Anti-insulin antibody
Normalized name: Anti-insulin antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-insulin antibody exposure in pancreatic islets
Study: 25063274
Drug: Glucagon treatment
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon treatment in islets pretreated with diazoxide or anti-insulin antibody
Study: 2446132
Drug: Immediate adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate adjuvant cisplatin‐based chemotherapy
Study: 2446132
Drug: Observation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation with treatment at relapse
Study: 11315838
Drug: Postprandial MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial MG and 3‐DG
Study: 29960605
Drug: Tailored activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored activity counselling intervention (IG) encouraging to increase daily step count by 5%
Study: 22367658
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg/d for 7 days)
Study: 22367658
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/d for 7 days)
Study: 22367658
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/d for 7 days)
Study: 15608524
Drug: lopinavir/ritonavir (LPV/rtv)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (LPV/rtv) 400/100 mg BID plus nevirapine (NVP) 200 mg BID (NVP group, n = 16)
Study: 2401128
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of felodipine (plasma concentration of 6 ng/ml after 20 minutes, sustained for 8 hours)
Study: 2401128
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of felodipine (plasma concentration of 6 ng/ml after 8 hours)
Study: 2401128
Drug: Control infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control infusions with saline and vehicle
Study: 399250
Drug: Cefaclor (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (3 x 500 mg)
Study: 399250
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 x 750 mg)
Study: 26395834
Drug: EU-RMP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-RMP (5 mg/kg)
Study: 26395834
Drug: US-RMP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-RMP (5 mg/kg)
Study: 21629997
Drug: Acute nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute nicotine (2 mg gum) in non-smokers
Study: 9734742
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg/d)
Study: 3058132
Drug: Spironolactone (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100-200 mg/d)
Study: 3058132
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (50-200 mg/d)
Study: 30342298
Drug: Pemafibrate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (0.2 mg twice daily)
Study: 18213545
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg/day for 3 weeks before, during, and 2 weeks after the race)
Study: 10985706
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy and/or intra-aortic balloon counter-pulsation, coronary angiography, angioplasty and/or coronary artery bypass surgery
Study: 10985706
Drug: Registry patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry patients managed with various treatments
Study: 9173382
Drug: Coumarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin plus low-dose acetylsalicylic acid (125 mg/day)
Study: 3993547
Drug: Atenolol (cardioselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (cardioselective beta-blocker)
Study: 31556650
Drug: Trauma-focused cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive-behavioral treatments (TF-CBT)
Study: 31556650
Drug: Present-Centered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-Centered Therapy (comparison arm in 2 trials)
Study: 23948637
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (SRI)
Study: 19218250
Drug: Posterior sub-Tenon
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior sub-Tenon capsule injection of triamcinolone acetonide (PSTA) 20 mg
Study: 14632810
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae suspension
Study: 14632810
Drug: Buffer solution
Normalized name: Buffer Solution, pH 5.00, Reference Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer solution (placebo)
Study: 2065534
Drug: Intrapartum amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum amnioinfusion for replacement (IAR) with normal saline solution
Study: 6627827
Drug: 5 gm
Normalized name: Olpruva 5 GM Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 gm activated charcoal every 2 hr for 6 doses
Study: 6627827
Drug: 20 gm
Normalized name: HYQVIA 20 GM / 200 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 gm activated charcoal every 2 hr for 6 doses
Study: 6627827
Drug: 40 gm
Normalized name: Gamunex 40 GM per 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 gm activated charcoal every 4 hr for 3 doses
Study: 3909842
Drug: serum protein
Normalized name: Serum protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: serum protein solution
Study: 27521283
Drug: DADDS-G (Death
Approvals — FDA: no, EMA: no, PMDA: no
Description: DADDS-G (Death and Dying Distress Scale)
Study: 9003465
Drug: Bestatin 90
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin 90 and 180 mg daily for 60 days
Study: 9003465
Drug: Bestatin 10
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin 10 and 30 mg daily for 60 days
Study: 6748872
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment (15 mg daily)
Study: 26337246
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (TXA)
Study: 27576483
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of etanercept and fumarates
Study: 24447116
Drug: Low-intensity (LI)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity (LI) condition (monthly phone calls, printed materials, community referrals)
Study: 19925875
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) plus high-dose corticosteroids
Study: 18574157
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with paclitaxel plus cisplatin followed by the same chemotherapy with 50.4 Gy of radiation (arm B)
Study: 12453928
Drug: i.m. bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. bupivacaine (5 mg ml(‐1)) 1 mg kg(‐1)
Study: 12453928
Drug: i.m. lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. lidocaine (100 mg ml(‐1)) 2 mg kg(‐1)
Study: 12453928
Drug: i.m. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. saline 5 ml
Study: 10703901
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h) during high salt (HS) diet
Study: 10703901
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h) during low salt (LS) diet
Study: 10703901
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h)
Study: 1743373
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream (pretreated side)
Study: 7072476
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg in 10 ml saline
Study: 7072476
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline (control)
Study: 7072476
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg in saline (if pain score exceeded 5)
Study: 30991969
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly injectable formulation (AOM)
Study: 14598513
Drug: Memantine (NMDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (NMDA receptor antagonist)
Study: 18829205
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin aspart every 2 h until BG < 200 mg/dL
Study: 18829205
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls with DM and an ED admission BG > 200 mg/dL
Study: 19515731
Drug: Large bite
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large bite size (approximately 15 g)
Study: 19515731
Drug: Small bite
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small bite size (approximately 5 g)
Study: 17083378
Drug: 2-week therapy
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week therapy with omeprazole, amoxicillin, and clarithromycin
Study: 17083378
Drug: 1-week therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week therapy with omeprazole, amoxicillin, and clarithromycin
Study: 22672578
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (CT) alone
Study: 29604186
Drug: Baminercept (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baminercept (100 mg subcutaneous injections every week for 24 weeks)
Study: 27709863
Drug: Steroid (TA)
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (TA) injection
Study: 27709863
Drug: Steroid (TA)
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (TA) injection (first)
Study: 27709863
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection (first)
Study: 27709863
Drug: Steroid (TA)
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (TA) first, Hyaluronic acid (HA) later
Study: 27709863
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) first, Steroid (TA) later